Business Context and Reporting Period
This Form 6-K filing by Alterity Therapeutics Limited, a development stage enterprise, covers the month of September 2023. The report was signed by Geoffrey P. Kempler, Chairman, on September 13, 2023.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document focuses on corporate notifications rather than financial performance data.
Material Changes
The primary material event disclosed is the cessation of securities trading for the ticker symbol "ATH," as detailed in Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors. The document serves primarily to incorporate the notification of the cessation of securities into existing Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Verify the status of the "ATH" ticker symbol and the implications of its cessation.
- Confirm the current listing status of Alterity Therapeutics Limited on relevant exchanges.
- Review the referenced Registration Statements (S-8 and F-3) for details on outstanding equity plans.
- Check for subsequent filings regarding the company's operational status as a development stage enterprise.